| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | ||||||||
Net income (loss) | ||||||||
-49,100 | -9,500 | 10,000 | 35,900 | 31,500 | 16,400 | 60,200 | -62,800 | 72,700 |
Adjustments to reconcile net income (loss) to cash flows from operating activities: | ||||||||
Depreciation and amortization | ||||||||
81,500 | 83,400 | 78,700 | 77,200 | 75,200 | 73,700 | 72,700 | 75,300 | 74,300 |
Change in deferred income taxes | ||||||||
-25,100 | -14,800 | -25,400 | 24,000 | 16,300 | -73,300 | 1,800 | 13,200 | -2,400 |
Stock-based compensation expense | ||||||||
11,100 | 12,700 | 14,800 | 14,200 | 7,700 | 5,800 | 6,900 | 6,400 | 6,900 |
Asset impairment charges | ||||||||
0 | 7,900 | 20,700 | 0 | 4,000 | 18,000 | 4,600 | 97,900 | 0 |
Gain on sale of assets | ||||||||
3,800 | - | - | - | 0 | - | - | - | - |
Changes in operating assets and liabilities | ||||||||
9,800 | - | 61,800 | 88,000 | 117,200 | - | - | - | - |
Other changes in operating assets and liabilities | ||||||||
- | - | - | - | - | - | - | - | 105,900 |
Other non-cash operating activities, net | ||||||||
-500 | 7,300 | 2,600 | -13,200 | -9,400 | 45,500 | 2,800 | -700 | 1,400 |
Other changes in operating assets and liabilities, net of acquisitions and divestitures: | ||||||||
Net Cash Provided by (Used for) Operating Activities | ||||||||
4,300 | 126,300 | 39,600 | 50,100 | 8,100 | 139,500 | 163,900 | 136,900 | 47,000 |
Cash Flows from Investing Activities | ||||||||
Net purchases of property and equipment | ||||||||
12,600 | 54,400 | 34,200 | 23,800 | 28,000 | 60,200 | 17,800 | 23,800 | 32,700 |
Proceeds from settlement of net investment hedges (Note 11) | ||||||||
25,200 | - | - | - | 0 | - | - | - | - |
Purchases of software | ||||||||
31,800 | - | - | - | 2,500 | - | - | - | - |
Other investing activities, net | ||||||||
400 | -36,800 | 16,000 | 25,200 | 500 | -4,700 | 3,600 | -700 | 1,700 |
Net Cash Used for Investing Activities | ||||||||
-19,600 | -74,300 | -83,000 | -46,500 | -31,000 | -48,100 | -21,400 | -23,100 | -34,400 |
Cash Flows from Financing Activities | ||||||||
Repayments of borrowings (Note 10) | ||||||||
371,400 | - | 50,000 | 57,500 | 7,500 | - | 0 | 0 | 0 |
Proceeds from issuance of long-term debt (Note 10) | ||||||||
79,200 | - | - | - | 0 | - | - | - | - |
Proceeds from issuance of common stock and tangible equity units (Note 9) | ||||||||
1,219,900 | - | - | - | 0 | - | - | - | - |
Debt issuance costs | ||||||||
3,100 | - | - | - | 0 | - | - | - | - |
Consideration paid to Lilly in connection with the Separation (Note 1) | ||||||||
0 | 0 | 400 | 16,100 | 175,100 | 432,200 | 3,559,100 | 0 | 0 |
Other net financing transactions with Lilly | ||||||||
-15,200 | 0 | 1,300 | 161,400 | -156,400 | 93,000 | -124,600 | -46,700 | -76,100 |
Other financing activities, net | ||||||||
-12,800 | -100 | 300 | 1,900 | -500 | -13,500 | -2,800 | -500 | -400 |
Net Cash Provided by (Used for) Financing Activities | ||||||||
896,600 | -6,200 | -48,800 | 89,700 | -339,500 | -362,400 | 450,900 | -47,200 | -76,500 |
Effect of exchange rate changes on cash and cash equivalents | ||||||||
-9,300 | -21,000 | 15,900 | 2,700 | -14,500 | 13,600 | 20,500 | -9,000 | 3,900 |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||||
872,000 | 24,800 | -76,300 | 96,000 | -376,900 | -257,400 | 613,900 | 57,600 | -60,000 |